Belimumab, a human monoclonal antibody that inhibits BAFF/BlyS, is approved for the treatment of systemic lupus erythematosus and may represent a potential drug candidate for the management of refractory sarcoidosis. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.